New asthma combo shows promise in early trial
NCT ID NCT02296411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a bronchodilator called glycopyrrolate bromide to a standard steroid inhaler (Qvar) helps people with uncontrolled asthma breathe better. 98 adults with asthma took either the combination or a placebo for 6 weeks, then switched. The main goal was to measure lung function over 12 hours. The results could point to a new treatment option for asthma that isn't fully controlled by steroids alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glycopyrrolate bromide (an inhaled bronchodilator)
What this could lead to
If successful, this could lead to a new combination inhaler that helps people with asthma breathe better when their current medication isn't enough.
What could go wrong
This is a small, early-phase study (98 people) testing short-term effects only. The added drug may not work for everyone, and long-term safety or benefit is not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiesi Clinical Trial Site 0101
Sofia, 1000, Bulgaria
-
Chiesi Clinical Trial Site 0102
Sofia, 1431, Bulgaria
-
Chiesi Clinical Trial Site 0103
Sofia, 1431, Bulgaria
-
Chiesi Clinical Trial Site 0106
Sevlievo, 5400, Bulgaria
-
Chiesi Clinical Trial Site 0107
Rousse, 7002, Bulgaria
-
Chiesi Clinical Trial Site 0108
Sofia, 1407, Bulgaria
-
Chiesi Clinical Trial Site 0109
Sofia, 1336, Bulgaria
-
Chiesi Clinical Trial Site 0201
Berlin, D-12165, Germany
-
Chiesi Clinical Trial Site 0202
Leipzig, 04357, Germany
-
Chiesi Clinical Trial Site 0203
Leipzig, 04207, Germany
-
Chiesi Clinical Trial Site 0206
Magdeburg, 39112, Germany
-
Chiesi Clinical Trial Site 0207
Radebeul, 01445, Germany
-
Chiesi Clinical Trial Site 0208
Witten, 58452, Germany
-
Chiesi Clinical Trial Site 0301
Pisa, 56124, Italy
-
Chiesi Clinical Trial Site 0303
Pordenone, 33170, Italy
-
Chiesi Clinical Trial Site 0304
Pisa, 56124, Italy
-
Chiesi Clinical Trial Site 0306
Brescia, 25123, Italy
-
Chiesi Clinical Trial Site 0404
Assen, 9401 RK, Netherlands
-
Chiesi Clinical Trial Site 0405
Helmond, 5707 HA, Netherlands
-
Chiesi Clinical Trial Site 0501
Bialystok, 15-010, Poland
-
Chiesi Clinical Trial Site 0502
Bialystok, 15-351, Poland
-
Chiesi Clinical Trial Site 0503
Elblag, 82-300, Poland
-
Chiesi Clinical Trial Site 0504
Krakow, 31-011, Poland
-
Chiesi Clinical Trial Site 0505
Wroclaw, 53-310, Poland
-
Chiesi Clinical Trial Site 0506
Zgierz, 95-100, Poland
-
Chiesi Clinical Trial Site 0507
Krakow, 30-349, Poland
-
Chiesi Clinical Trial Site 0510
Lodz, 90-252, Poland
-
Chiesi Clinical Trial Site 0512
Lodz, 90-141, Poland